Inventor · disambiguated record
Christopher Daly
Also filed as: DALY CHRISTOPHER · DALY CHRISTOPHER J
43 granted patents·17 pending applications·191 citations·filing 1998–2025
97Inventor score
Files withREGENERON PHARMA27AMERA IOT INC14JOHNSON MATTHEY PLC13NUWAVE TECHNOLOGIES INC2THURSTON GAVIN2
Top patents by PatentIndex Score
60 records- 0198US9132192B2Anti-EGFR antibodies and uses thereofREGENERON PHARMA·Filed 2013·Granted Sep 15, 2015·72 cites·4 claims
- 0296US11845064B2Composite, zoned oxidation catalyst for a compression ignition internal combustion engineJOHNSON MATTHEY PLC·Filed 2020·Granted Dec 19, 2023·7 cites·16 claims
- 0395US8980268B2Methods for treating cancer by administering an anti-Ang-2 antibodyREGENERON PHARMA·Filed 2013·Granted Mar 17, 2015·16 cites·26 claims
- 0493US11142578B2Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereofREGENERON PHARMA·Filed 2017·Granted Oct 12, 2021·6 cites·26 claims
- 0593US10817590B1Method and apparatus for creating and using quantum resistant keysAMERA IOT INC·Filed 2020·Granted Oct 27, 2020·17 cites·28 claims
- 0691US8791244B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2012·Granted Jul 29, 2014·12 cites·8 claims
- 0790US8987420B2High affinity human antibodies to human angiopoietin-2THURSTON GAVIN·Filed 2010·Granted Mar 24, 2015·15 cites·10 claims
- 0887US9273143B2Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibodyREGENERON PHARMA·Filed 2013·Granted Mar 1, 2016·6 cites·24 claims
- 0986US10632194B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Apr 28, 2020·2 cites·8 claims
- 1086US9827310B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Nov 28, 2017·4 cites·12 claims
- 1185US11965161B2Methods and compositions for sensitization of tumor cells to immune therapyREGENERON PHARMA·Filed 2021·Granted Apr 23, 2024·1 cites·45 claims
- 1285US9284380B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2014·Granted Mar 15, 2016·5 cites·23 claims
- 1384US11958910B2Bispecific antigen binding molecules that bind HER2, and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Apr 16, 2024·1 cites·22 claims
- 1482US11681783B2Method and apparatus for creating and using quantum resistant keysAMERA IOT INC·Filed 2022·Granted Jun 20, 2023·1 cites·20 claims
- 1582US11256783B2Method and apparatus for simultaneous key generation on device and server for secure communicationAMERA IOT INC·Filed 2021·Granted Feb 22, 2022·1 cites·12 claims
- 1682US10861352B2Ophthalmological teaching aidWELCH ALLYN INC·Filed 2018·Granted Dec 8, 2020·3 cites·20 claims
- 1781US11258602B2Method and apparatus for secure private key storage on IoT deviceAMERA IOT INC·Filed 2020·Granted Feb 22, 2022·1 cites·10 claims
- 1880US12362928B2Method and apparatus for secure private key storage on IoT deviceAMERA IOT INC·Filed 2024·Granted Jul 15, 2025·0 cites·8 claims
- 1979US12296319B2Composite, zoned oxidation catalys for a compression ignition internal combustion engineJOHNSON MATTHEY PLC·Filed 2023·Granted May 13, 2025·0 cites·20 claims
- 2078US12353518B2Method and apparatus for simultaneous key generation on device and server for secure communicationAMERA IOT INC·Filed 2024·Granted Jul 8, 2025·0 cites·12 claims
- 2178US11271911B2Method and apparatus for imprinting private key on IoTAMERA IOT INC·Filed 2020·Granted Mar 8, 2022·1 cites·18 claims
- 2278US2025288980A1Composite, zoned oxidation catalyst for a compression ignition internal combustion engineJOHNSON MATTHEY PLC·Filed 2025·Application pending·0 cites
- 2377US12026236B2Method and apparatus for creating and using quantum resistant keysAMERA IOT INC·Filed 2023·Granted Jul 2, 2024·0 cites·18 claims
- 2476US2025250342A2Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2575US11983251B2Method and apparatus for simultaneous key generation on device and server for secure communicationAMERA IOT INC·Filed 2023·Granted May 14, 2024·0 cites·12 claims
- 2674US11997202B2Method and apparatus for secure private key storage on IoT deviceAMERA IOT INC·Filed 2023·Granted May 28, 2024·0 cites·9 claims
- 2774US10357743B2Oxidation catalyst for a diesel engine exhaustJOHNSON MATTHEY PLC·Filed 2016·Granted Jul 23, 2019·1 cites·26 claims
- 2874US2024190973A1Anti-fgfr2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2973US9789184B2Anti-EGFR antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 17, 2017·1 cites·13 claims
- 3073US2023191379A1Emissions control deviceJOHNSON MATTHEY PLC·Filed 2023·Application pending·0 cites
- 3172US11866502B2Anti-FGFR2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Jan 9, 2024·0 cites·65 claims
- 3272US11771762B2Anti-ErbB3 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Oct 3, 2023·0 cites·19 claims
- 3372US10179325B2Exhaust system for a compression ignition engine having a capture region for volatilised platinumJOHNSON MATTHEY PLC·Filed 2016·Granted Jan 15, 2019·1 cites·20 claims
- 3471US11637698B2Method and apparatus for secure private key storage on IoT deviceAMERA IOT INC·Filed 2022·Granted Apr 25, 2023·0 cites·10 claims
- 3570US2021101969A1High Affinity Human Antibodies to Human Angiopoietin-2REGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3669US9371379B2Methods for treating malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)REGENERON PHARMA·Filed 2013·Granted Jun 21, 2016·1 cites·8 claims
- 3768US11625455B2Method and apparatus for simultaneous key generation on device and server for secure communicationAMERA IOT INC·Filed 2022·Granted Apr 11, 2023·0 cites·12 claims
- 3867US10875911B2High affinity human antibodies to human angiopoietin-2REGENERON PHARMA·Filed 2018·Granted Dec 29, 2020·0 cites·20 claims
- 3966US2024158515A1Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4065US2024173426A1Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4164US12343714B2Composite, zoned oxidation catalyst for a compression ignition internal combustion engineJOHNSON MATTHEY PLC·Filed 2020·Granted Jul 1, 2025·0 cites·16 claims
- 4263US11308183B2Method and apparatus for creating and using quantum resistant keysAMERA IOT INC·Filed 2020·Granted Apr 19, 2022·0 cites·20 claims
- 4363US2024247069A1Fgfr3 binding molecules and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4463US2019299159A1Oxidation catalyst for a diesel engine exhaustJOHNSON MATTHEY PLC·Filed 2019·Application pending·0 cites
- 4560US2023323802A1Exhaust gas treatment systemJOHNSON MATTHEY PLC·Filed 2023·Application pending·0 cites
- 4659US12225125B2Method and apparatus for using a picture and shared secret to create replicable high quality pools of entropy for keys for encryption, authentication and one time pads for images, data and message encodingAMERA IOT INC·Filed 2024·Granted Feb 11, 2025·0 cites·1 claims
- 4755US11618014B2Method of coating a substrate with a particle stabilized foamJOHNSON MATTHEY PLC·Filed 2017·Granted Apr 4, 2023·0 cites·14 claims
- 4855US9938339B2Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2REGENERON PHARMA·Filed 2015·Granted Apr 10, 2018·0 cites·7 claims
- 4955US2018036405A1Anti-EGFR Antibodies and Uses ThereofREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 5054US9926369B2Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibodyREGENERON PHARMA·Filed 2015·Granted Mar 27, 2018·0 cites·10 claims
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christopher Daly files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →